3.13 USD
+0.34 (+12.19%)
Last: Jan 9, 2023, 08:23 PM
MTBC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. While MTBC seems to be doing ok healthwise, there are quite some concerns on its profitability. MTBC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- MTBC had negative earnings in the past year.
- In the past year MTBC had a positive cash flow from operations.
1.2 Ratios
- MTBC has negative profitability rations, so we won't be analyzing them here.
- MTBC has a better Return On Invested Capital (4.81%) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | 4.81% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Operating Margin, with a value of 3.77%, MTBC is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
- The Gross Margin of MTBC (38.04%) is worse than 62.22% of its industry peers.
- In the last couple of years the Gross Margin of MTBC has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.77% | ||
| PM (TTM) | N/A | ||
| GM | 38.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5Y-3.59%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MTBC is destroying value.
- The number of shares outstanding for MTBC has been increased compared to 1 year ago.
- The debt/assets ratio for MTBC is higher compared to a year ago.
2.2 Solvency
- MTBC has an Altman-Z score of 2.01. This is not the best score and indicates that MTBC is in the grey zone with still only limited risk for bankruptcy at the moment.
- MTBC has a Altman-Z score of 2.01. This is in the better half of the industry: MTBC outperforms 62.22% of its industry peers.
- MTBC has a debt to FCF ratio of 0.06. This is a very positive value and a sign of high solvency as it would only need 0.06 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.06, MTBC belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
- MTBC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of MTBC (0.00) is better than 68.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 2.01 |
ROIC/WACC0.61
WACC7.84%
2.3 Liquidity
- A Current Ratio of 1.21 indicates that MTBC should not have too much problems paying its short term obligations.
- MTBC has a Current ratio of 1.21. This is in the lower half of the industry: MTBC underperforms 68.89% of its industry peers.
- MTBC has a Quick Ratio of 1.19. This is a normal value and indicates that MTBC is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of MTBC (1.19) is worse than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 56.73% over the past year.
- MTBC shows a small growth in Revenue. In the last year, the Revenue has grown by 7.14%.
- The Revenue has been growing by 41.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)56.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y40.35%
Revenue growth 5Y41.63%
Sales Q2Q%-11.96%
3.2 Future
- MTBC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.25% yearly.
- MTBC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.57% yearly.
EPS Next Y13.69%
EPS Next 2Y7.89%
EPS Next 3Y16.8%
EPS Next 5Y6.25%
Revenue Next Year0.64%
Revenue Next 2Y1.19%
Revenue Next 3Y3.72%
Revenue Next 5Y2.57%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- MTBC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MTBC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 100.00% of the companies in the same industry are more expensive than MTBC, based on the Enterprise Value to EBITDA ratio.
- MTBC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MTBC is cheaper than 97.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.4 | ||
| EV/EBITDA | 2.55 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MTBC's earnings are expected to grow with 16.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.89%
EPS Next 3Y16.8%
5. Dividend
5.1 Amount
- MTBC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MTBC (1/9/2023, 8:23:58 PM)
3.13
+0.34 (+12.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-03 2022-11-03/bmo
Earnings (Next)03-13 2023-03-13
Inst Owners11.55%
Inst Owner Change9.38%
Ins Owners0.89%
Ins Owner Change0%
Market Cap47.61M
Revenue(TTM)143.75M
Net Income(TTM)-6.85M
Analysts83.64
Price Target9.69 (209.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP-220.54%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.24%
Min EPS beat(2)4.61%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)48.06%
Min EPS beat(4)4.61%
Max EPS beat(4)94.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.73%
Min Revenue beat(2)-3.14%
Max Revenue beat(2)-2.32%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-3.14%
Max Revenue beat(4)2.51%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.54%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.33 | ||
| P/FCF | 5.4 | ||
| P/OCF | 2.24 | ||
| P/B | 0.46 | ||
| P/tB | 4.01 | ||
| EV/EBITDA | 2.55 |
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)0.58
FCFY18.5%
OCF(TTM)1.4
OCFY44.58%
SpS9.45
BVpS6.76
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | 4.81% | ||
| ROICexc | 4.99% | ||
| ROICexgc | 43.34% | ||
| OM | 3.77% | ||
| PM (TTM) | N/A | ||
| GM | 38.04% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5Y-3.59%
F-Score4
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 103.98% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.01 |
F-Score4
WACC7.84%
ROIC/WACC0.61
Cap/Depr(3y)81.08%
Cap/Depr(5y)58.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y13.69%
EPS Next 2Y7.89%
EPS Next 3Y16.8%
EPS Next 5Y6.25%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y40.35%
Revenue growth 5Y41.63%
Sales Q2Q%-11.96%
Revenue Next Year0.64%
Revenue Next 2Y1.19%
Revenue Next 3Y3.72%
Revenue Next 5Y2.57%
EBIT growth 1Y261.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1308.1%
EBIT Next 3Y177.57%
EBIT Next 5Y93.09%
FCF growth 1Y213.67%
FCF growth 3Y-21.74%
FCF growth 5YN/A
OCF growth 1Y1553.9%
OCF growth 3Y25.1%
OCF growth 5YN/A
CARECLOUD INC / MTBC FAQ
Can you provide the ChartMill fundamental rating for CARECLOUD INC?
ChartMill assigns a fundamental rating of 3 / 10 to MTBC.
What is the valuation status for MTBC stock?
ChartMill assigns a valuation rating of 3 / 10 to CARECLOUD INC (MTBC). This can be considered as Overvalued.
How profitable is CARECLOUD INC (MTBC) stock?
CARECLOUD INC (MTBC) has a profitability rating of 1 / 10.
Can you provide the financial health for MTBC stock?
The financial health rating of CARECLOUD INC (MTBC) is 4 / 10.
What is the earnings growth outlook for CARECLOUD INC?
The Earnings per Share (EPS) of CARECLOUD INC (MTBC) is expected to grow by 13.69% in the next year.